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Available online 6 April 2016Aim: Low adherence to cardiovascular medications is often difﬁcult to monitor and is associated with adverse
outcomes. We investigated whether there is a difference between the estimated adherence (EA) of the two-
dosed regimens of apixaban (A) and the one-dosed regimen of rivaroxaban (R) for stroke prophylaxis in patients
with non-valvular atrial ﬁbrillation (AF).
Method and results: This is a retrospective cohort study of AF patients referred to a well-structured nurse-based
AF unit for the initiation of anticoagulation therapy. The adherence datawas extracted from the Swedish national
prescribed drug register. EA was calculated by dividing the number of daily doses dispensed from the prescrip-
tion that occurred closest after 3 months from the ﬁrst dispensed prescription of the respective agent until
(but excluding) the last reﬁll by the number of days in the interval. The study included 123 patients on A and
227 patients on R with a 12-month follow-up period. There were no signiﬁcant demographic differences be-
tween the two patient groups except for previous vitamin K antagonist treatment, in the A patient group
(n = 29, 24%) and in the R (n = 31, 14%), p = 0.025. The mean ± SD of EA after 3 months was high for both
A 97 ± 7 (n = 112) and R 97 ± 9 (n = 197) p = 0.97. The EA ≥80% was for A 97% (n = 109) and for R 96%
(n = 189) p = 0.43.
Conclusion: The two dosed regimens of apixaban and the one dosed regimen of rivaroxaban showed similar high
estimated adherence when administered for stroke prophylaxis in patients with AF in a well-structured nurse-
based AF clinic.







The non-vitaminK antagonist oral anticoagulants (NOACs) are supe-
rior in efﬁcacy and safety compared to vitamin K antagonists (VKA)
when used for stroke prophylaxis in patients with non-valvular atrial ﬁ-
brillation (AF) [1–3]. The NOACs offer life style advantages due to fast
dosing regimen, lack of regular routine laboratorymonitoring of the he-
mostatic system and signiﬁcantly less interactions with food products
and medical preparations.
However there are concerns that the lack of regular monitoring of
the coagulation level might make it difﬁcult to assess and enhance the
drug adherence. Low adherence in AF patients taking NOACs was
shown to be associated with higher mortality and morbidity [4].
Once daily dosed medication had been shown to have better adher-
ence rates in comparison to twice daily dosed regimens in case ofngsgatan 34, 111 35 Stockholm,
catrine.lindstrom@shc.se
. This is an open access article undercardiovascular medications [5]. Therefore we planned this study to as-
sess and compare adherence levels between the one-dosed regimen of
rivaroxaban and the two-dosed regimens of apixaban among patients
with non-valvular AF in a real world clinical setting within the frame-
work of a well-structured atrial ﬁbrillation clinic.
2. Methods
This is a retrospective cohort study of AF patients referred to our unit
for initiation of NOACs in the period between December 2011 and May
2014. All the patients were treated in a single institution, which is a
large tertiary referral cardiology outpatient clinic that incorporates a
well-structured, nurse-based AF unit. The unit's nurses initiate NOAC
treatment for patients with AF assessed initially by a referring cardiolo-
gist. The unit nurses review the treatment indication, the bleeding risk,
provide information about the treatment, and give patient support dur-
ing the follow-up period.
The nurse suggests to the referring cardiologist a follow-up plan and
in addition they stand for future patient support during the follow-up
period at the clinic. Patients are encouraged to make prompt contactthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1






Age 72 + 8 73 + 8 0.56
Female 57 (46%) 112 (49%) 0.65
Male 66 (54%) 115 (51%)
Body Mass Index 26 + 4 26 + 5 0.50
Prior antiplatelet 49 (40%) 85 (37%) 0.73
Prior VKA 29 (24%) 31 (14%) 0.03
Standard dose 102 (83%) 184 (81%) 0.77
Reduced dose 21 (17%) 43 (19%)
CHA2DS2-VASc score 3 (2–4) 3 (2–4) 0.26
Heart failure 13 (11%) 23 (10%) 1.00
Hypertension 77 (63%) 153 (67%) 0.41
Diabetes mellitus 10 (8%) 25 (11%) 0.46
Stroke 14 (11%) 13 (6%) 0.09
Acute myocardial infarction 12 (10%) 11 (5%) 0.11
Peripheral artery disease 3 (2%) 6 (3%) 1.00
Glomerular ﬁltration rate* 79 ± 25 79 ± 26 0.96
Categorical variables are presented with n (%) and tested with Fisher Exact Test, continu-
ous variables are presented with mean ± SD or median (q1–q3) and tested with t-test or
Man–Whitney U test respectively. VKA: Vitamin K antagonist. * ml/min, calculated using
Cockroft–Gault.
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planned interventions that might necessitate study withdrawal, and
even in case they for some reasondecide orwish to stop theNOAC treat-
ment. All patients had a scheduled appointment with the cardiologist 3
and 12 months after the initiation of the NOAC therapy. We did not in-
clude any patient with persistent atrial ﬁbrillation requiring NOAC tem-
porally for scheduled elective cardioversion.
The CHA2DS2-VASc score scale was used to estimate the risk of
stroke. The score takes into account age, gender, congestive heart failure
(current diagnosis of heart failure or left ventricular ejection fraction
b40%), hypertension and/or diabetes mellitus requiring pharmacologi-
cal treatment, and previous diagnosis of stroke/transient ischemic at-
tack (TIA) or systemic embolism, vascular disease. Previous
antiplatelet therapy comprised prior use of oral acetylsalicylic acid or
clopidogrel that was stopped immediately or shortly before the start
of NOAC therapy and the same for prior VKA therapy, which was either
stopped shortly before or switched immediately to NOAC.
The estimated adherence was calculated by dividing the number of
daily doses dispensed from the prescription that occurred closest after
3 months from the ﬁrst dispensed prescription of the respective NOAC
until (but excluding) the last reﬁll by the number of days in the interval.
Since rivaroxaban entered the market prior to apixaban we only in-
cluded data for the ﬁrst year following the ﬁrst prescription in order
to make the two groups comparable regarding follow-up time. Patients
that did not have 12month follow-upwere excluded. A patient was de-
ﬁned as discontinued if the number of daily doses from the last reﬁll did
not last until the end of the 12-month period. In order to take into ac-
count possible non-adherence or saved doses from previous reﬁlls, we
allowed a gap of 30 days from the last dose. However, if a patient was
deﬁned as discontinued, discontinuation was assumed to occur after
half of the daily doses from the last reﬁll. The adherence and persistence
data was extracted from the Swedish national prescribed drug register
since each resident in Sweden has a unique personal identiﬁcation
number. The Register performs online with automat registration of all
dispensed prescriptions from all pharmacies throughout Sweden.
2.1. Ethics
The study complies with the Declaration of Helsinki, and the study
protocol was approved by the regional ethics committee (DNR: 2014/
738-31) and the Swedish Board of Health and Welfare (DNR: 30457/
2014).
2.2. Statistics
Baseline characteristicswere tested for distributional differences be-
tween apixaban and rivaroxaban using Fisher Exact test for categorical
variables and t-test or Mann–Whitney U test for continuous variables.
To compare outcomes (adherence and persistence) between the two
groups Generalized Estimating Equation (GEE) models were used. Due
to the small sample size we restricted adjustment to those variables
that differed statistically signiﬁcant between the two NOACs. Time to
discontinuation was graphically presented in a Kaplan–Meier curve
and tested with the log-rank test.
The level of signiﬁcance was set to 5%, two-sided. All calculations
were performed using R v 3.1.3 (R Foundation for Statistical Computing,
Vienna, Austria).
3. Results
The study included 127 patients on apixaban and 249 patients on
rivaroxiban with a 12-month follow-up period. We then excluded pa-
tients who had only one prescription reﬁll (3 apixaban and 21
rivaroxaban) and those who died during the follow-up period (1
apixaban and 1 rivaroxaban). Then for the calculation of the estimated
adherence we excluded the ﬁrst 3 months of treatment making theﬁnal number of patients 112 on apixaban and 197 on rivaroxaban. The
total observation time (median, q1–q3) excluding the ﬁrst 3 months
of treatment was 184 (157–212) for apixaban and 188 (150–204) for
rivaroxaban. The patient's clinical characteristics are described in
Table 1. There were no signiﬁcant differences between the patients on
the two therapies except for previous VKA treatment for which there
were more patients in the apixaban patient group (29, 24%) than in
the rivaroxaban patient group (31, 14%), p = 0.025.
The number of patients that discontinued rivaroxaban was 39 (17%)
and for apixaban was 16 (13%), which showed no statistical difference.
The Kaplan–Meyer curve for discontinuation rates is shown in Fig. 1.
The risk ratio for discontinuation unadjusted is 1.32 (95% CI 0.77–
2.26) p-value = 0.312, and risk ratio adjusted for prior VKA 1.28 (95%
CI 0.75–2.21) p-value = 0.365.
The estimated mean andmedian adherence rates after 3 months for
apixaban and rivaroxaban and the number of patients' adherence ≥80%
are shown in Table 2.
The adherence rate including the initial 3 months was for apixaban,
mean ± SD (96 ± 13) and for rivaroxaban (97 ± 9) p = 0.45, the me-
dian adherence rate (q1-13) was for apixaban 100 (100–100) and for
rivaroxaban 100 (100–100) p = 0.67. The adherence rate ≥ 80% was
for apixaban 95% (n = 117) and for rivaroxaban 96% (n = 218) p =
0.78.
The risk ratio for adherence ≥80% unadjusted is 1.52 (95% CI 0.41–
5.60) p-value = 0.532, and risk ratio adjusted for prior VKA is 1.54
(95% CI 0.41–5.72) p-value = 0.523.
There were no whatever signiﬁcant differences between the patient
group with high adherence ≥80% and those with poor adherence b80%
(Table 3).
4. Discussion
Our study shows a very high estimated adherence levels for both
apixaban and rivaroxaban when initiated in a well-structured atrial ﬁ-
brillation clinic and no statistically signiﬁcant difference in persistence
during one-year treatment time. There was no signiﬁcant difference in
the overall adherence level and higher adherence (≥80%) between the
two-dosed regimens of apixaban and the one-dosed regimen of
rivaroxaban.
The ﬁndings are of extreme importance considering the short half-
life of the NOAC and the lack of any mean of detecting and following
the patient's adherence to the agent. These considerations have raised
fears taking into account the high costs of the NOAC drugs and that a
Fig. 1. Kaplan–Meyer curve of the discontinuation rates of patients on apixaban and
rivaroxaban during 12 month period.
Table 3
Characteristics of the patients with adherence b 80% compared with those with adequate
adherence.
Adherence after 3 months
Variable b80% (n = 11) ≥80% (n = 298) p-value
Treatment duration, days
Mean ± SD 170 ± 38 179 ± 50 0.58
Median (q1–q3) 163 (142–186) 186 (156–208) 0.26
Female 6 (55) 141 (47) 0.76
Male 5 (45%) 157 (53%)
Age 74 ± 11 72 ± 8 0.59
Body Mass Index 24 ± 4 27 ± 5 0.12
Prior VKA 2 (18%) 51 (17%) 1.00
None 9 (82%) 247 (83%)
CHADSVASc 4 (2–4) 3 (2–4) 0.50
Creatinine clearancea 73 ± 30 80 ± 25 0.36
Categorical variables are presented with n (%) and tested with Fisher Exact Test, continu-
ous variables are presented with mean + SD or median (q1–q3) (min–max) and tested
with ANOVA or Kruskal–Wallis test respectively.
a GFR calculated by Cocroft–Gault formula.
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stroke, which would then double the health system and personal costs.
A once daily dosed regimen of NOAC had been suggested to yield
better adherence rates in comparison to twice daily dosed regimens
since there seems to be a general concern that drug adherence is inverse
to the number of doses per day.
Warfarin treatment for AF related stroke has been shown to be asso-
ciated with 45% low adherence (b80%) in a study on pharmacy reﬁll
data from drug prescription data in Sweden [6]. However adherence
to the two dosed regimens of dabigatran has been proven to be much
better in the data from the Veterans Administration Health study, in
which the ≥80% adherence was 72% using the proportion of days cov-
ered method to calculate the adherence [4]. In this study the majority
was men 98.3% and the mean age was 71.3 years. In addition a nation-
wide cohort study in Denmark showed a 76.8% of the AF patients taking
dabigatran hade ≥80% adherence after 1 year using the proportion of
days covered [7]. Persistence has also been shown to be higher for pa-
tients taking dabigatran than for warfarin at one year (63% versus
39%) in a study by the United States Department of Defense administra-
tive claims [8].
A clinical trial study of patients taking dabigatran versuswarfarin for
patients with acute deep venous thromboembolism showed a very high
adherence of 98% [9]. This high adherence wasmost probably driven by
frequent follow-up in the trial with the procedure of regular pill counts.
In addition clinical trials tend to exclude patients with previous serious
adverse events.
However a high adherence (88% of the patients had adherence
≥80%) was also shown by a clinical practice study of small cohort of pa-
tients taking dabigtran in a single thrombosis clinic [10].Table 2






Adherence, mean ± SD 97 ± 7 97 ± 9 0.97
Adherence, median (q1–q3) 100 (99–100) 100 (98–100) 0.82
Adherence ≥ 80%, n (%) 109 (97%) 189 (96%) 0.43Recent paper from Germany assessing the adherence to NOACs for
one year based on the proportion of days covered ≥80% showed signif-
icantly higher adherence in rivaroxaban users (72.2%) compared to
dabigatran (67.2%) and apixaban (69.5%) users [11].
In our study the high adherence in both rivaroxaban and apixaban
users is probably attributed not only to proper patient education using
motivational interviewing but also to proper patient selection and
very well structured patient support and follow-up system.
Shore s. et al. showed that patient education alone is inferior to ap-
propriate patient selection or patient adverse events monitoring to en-
hance dabigatran adherence in different prescription sites [12].
The limitation of the study is that it was retrospective and that the
estimated adherence method we used to calculate adherence using
the pharmacy reﬁll data is not fully reliable as no any other available
method neither [13]. Others are the small study population and that
the study did not extend more than one-year treatment in looking at
the adherence data.
5. Conclusion
Our study shows a high estimated adherence for both the two-dosed
regimen of apixaban and the one-dosed regimen of rivaroxaban when
administered for stroke prophylaxis in patients with non-valvular atrial
ﬁbrillation. There was no difference in the estimated adherence be-
tween the two agents of different dosed regimens.
Conﬂict of interests
Faris Al-Khalili and Catrine Lindström received honorarium for act-
ing as speakers for Bayer, Boehringer Ingelheim and Pﬁzer.
References
[1] Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2009;
361(12):1139–51.
[2] Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, HackeW, et al. Rivaroxaban versus
warfarin in nonvalvular atrial ﬁbrillation. N Engl J Med 2011;365(10):883–91.
[3] Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial ﬁbrillation. N Engl J Med 2011;
365(11):981–92.
[4] Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adher-
ence to dabigatran therapy and longitudinal patient outcomes: insights from the
veterans health administration. Am Heart J 2014;167(6):810–7.
[5] Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing fre-
quency and medication adherence in chronic disease. J Manag Care Pharm JMCP
2012;18(7):527–39.
[6] Skeppholm M, Friberg L. Adherence to warfarin treatment. Clin Res Cardiol 2014;
103(12):998–1005.
4 F. Al-Khalili et al. / Clinical Trials and Regulatory Science in Cardiology 18 (2016) 1–4[7] Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran
adherence in atrial ﬁbrillation patients during the ﬁrst year after diagnosis: a nation-
wide cohort study. J Thromb Haemost JTH 2015;13(4):495–504.
[8] Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, et al. Higher persistence in
newly diagnosed nonvalvular atrial ﬁbrillation patients treated with dabigatran ver-
sus warfarin. Circ Cardiovasc Qual Outcomes 2013;6(5):567–74.
[9] Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N
Engl J Med 2009;361(24):2342–52.
[10] Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treat-
ment with dabigatran in a real-world setting. J Thromb Haemost JTH 2013;11(7):
1295–9.[11] McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B, et al. Ad-
herence to non-vka oral anticoagulant medications based on the pharmacy quality
alliance measure. Curr Med Res Opin 2015;1-16.
[12] Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F, et al. Site-
level variation in and practices associated with dabigatran adherence. J Am Med
Assoc 2015;313(14):1443–50.
[13] Suryanarayan D, Schulman S. When the rubber meets the road: adherence and per-
sistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagu-
lants in the real world-a problem or a myth? Semin Thromb Hemost 2014;40(8):
852–9.
